JPWO2023051683A5 - - Google Patents
Info
- Publication number
- JPWO2023051683A5 JPWO2023051683A5 JP2024520079A JP2024520079A JPWO2023051683A5 JP WO2023051683 A5 JPWO2023051683 A5 JP WO2023051683A5 JP 2024520079 A JP2024520079 A JP 2024520079A JP 2024520079 A JP2024520079 A JP 2024520079A JP WO2023051683 A5 JPWO2023051683 A5 JP WO2023051683A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- seq
- variable region
- set forth
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111149114 | 2021-09-29 | ||
| CN202111149114.9 | 2021-09-29 | ||
| PCT/CN2022/122556 WO2023051683A1 (zh) | 2021-09-29 | 2022-09-29 | 抗lag3双特异性抗体、药物组合物及用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024538669A JP2024538669A (ja) | 2024-10-23 |
| JPWO2023051683A5 true JPWO2023051683A5 (enExample) | 2025-10-07 |
Family
ID=85770153
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519329A Pending JP2024536881A (ja) | 2021-09-29 | 2022-09-28 | 抗ｌａｇ３抗体、医薬組成物、及び使用 |
| JP2024520079A Pending JP2024538669A (ja) | 2021-09-29 | 2022-09-29 | 抗ｌａｇ３二重特異性抗体、医薬組成物、及び使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519329A Pending JP2024536881A (ja) | 2021-09-29 | 2022-09-28 | 抗ｌａｇ３抗体、医薬組成物、及び使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20250042995A1 (enExample) |
| EP (2) | EP4410835A4 (enExample) |
| JP (2) | JP2024536881A (enExample) |
| KR (2) | KR20240083095A (enExample) |
| CN (2) | CN115873116A (enExample) |
| AU (2) | AU2022355381A1 (enExample) |
| CA (2) | CA3233205A1 (enExample) |
| IL (2) | IL311738A (enExample) |
| MX (2) | MX2024003936A (enExample) |
| WO (2) | WO2023051621A1 (enExample) |
| ZA (2) | ZA202403273B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4008351A4 (en) * | 2019-08-02 | 2023-08-09 | CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. | Anti-pd-1 antibody and medical use thereof |
| IL311738A (en) * | 2021-09-29 | 2024-05-01 | Akeso Biopharma Inc | ANTI-LAG3 antibody, drug composition and use |
| CN117159703B (zh) * | 2023-11-02 | 2024-04-02 | 正大天晴(广州)医药有限公司 | 含抗lag-3抗体的药物组合物及其用途 |
| CN120714022A (zh) * | 2024-03-27 | 2025-09-30 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
| CN120919303A (zh) * | 2024-05-10 | 2025-11-11 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
| CN120518768B (zh) * | 2025-05-30 | 2025-12-30 | 中国人民解放军军事科学院军事医学研究院 | 抗lag-3的单克隆抗体、抗pd-1与lag-3的双特异性抗体、制备方法及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| SI3508502T1 (sl) * | 2013-09-20 | 2023-07-31 | Bristol-Myers Squibb Company | Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev |
| KR20160106762A (ko) | 2014-01-28 | 2016-09-12 | 브리스톨-마이어스 스큅 컴퍼니 | 혈액 악성종양을 치료하기 위한 항-lag-3 항체 |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CN106632674B (zh) | 2015-10-30 | 2018-11-16 | 泽达生物医药有限公司 | 一种抗pd-1单克隆抗体、其药物组合物及其用途 |
| WO2017106129A1 (en) * | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
| CA3026151A1 (en) * | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| TW201831513A (zh) * | 2016-06-20 | 2018-09-01 | Ｆ星貝塔有限公司 | 結合物件(一) |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN106977602B (zh) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| PL3606955T3 (pl) * | 2017-04-05 | 2025-02-24 | F. Hoffmann-La Roche Ag | Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3 |
| WO2018217940A2 (en) * | 2017-05-24 | 2018-11-29 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
| KR102713203B1 (ko) * | 2017-05-30 | 2024-10-10 | 브리스톨-마이어스 스큅 컴퍼니 | Lag-3 양성 종양의 치료 |
| WO2019120269A1 (zh) * | 2017-12-22 | 2019-06-27 | 江苏恒瑞医药股份有限公司 | Lag-3抗体药物组合物及其用途 |
| WO2019148412A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| CN110615840A (zh) * | 2018-06-19 | 2019-12-27 | 信达生物制药(苏州)有限公司 | 全人源的抗lag-3抗体及其应用 |
| JP7177543B2 (ja) * | 2018-08-21 | 2022-11-24 | エービーエル バイオ インコーポレイテッド | 抗ｐｄ－ｌ１／抗ｌａｇ３二重特異性抗体およびその使用 |
| CN115340606B (zh) * | 2019-05-31 | 2023-12-19 | 瑞阳(苏州)生物科技有限公司 | 与人lag-3蛋白结合的抗体及其编码基因和应用 |
| CN112079925B (zh) * | 2019-06-13 | 2025-04-25 | 上海健信生物医药科技有限公司 | 靶向lag-3的抗体和双特异性抗体及其用途 |
| EP4039704A4 (en) * | 2019-09-30 | 2023-09-20 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | ANTI-PD-1 ANTIBODIES AND USE THEREOF |
| KR20220104033A (ko) * | 2019-11-25 | 2022-07-25 | 아케소 바이오파마, 인크. | 항-pd-1-항-vegfa 이중특이항체, 약학 조성물 및 이의 용도 |
| US20230056230A1 (en) * | 2019-12-23 | 2023-02-23 | Macrogenics, Inc. | Therapy for the Treatment of Cancer |
| CN113348182B (zh) * | 2019-12-30 | 2022-07-12 | 上海海路生物技术有限公司 | Lag-3抗体及其医药用途 |
| BR112022013544A2 (pt) * | 2020-01-21 | 2022-09-06 | Shanghai Henlius Biotech Inc | Anticorpo monoclonal anti-lag3 e método de preparação do mesmo e uso do mesmo |
| CN118530341A (zh) * | 2021-03-12 | 2024-08-23 | 中山康方生物医药有限公司 | 提高含有免疫球蛋白Fc片段的药物的有效性的方法 |
| IL311738A (en) * | 2021-09-29 | 2024-05-01 | Akeso Biopharma Inc | ANTI-LAG3 antibody, drug composition and use |
-
2022
- 2022-09-28 IL IL311738A patent/IL311738A/en unknown
- 2022-09-28 EP EP22875004.8A patent/EP4410835A4/en active Pending
- 2022-09-28 AU AU2022355381A patent/AU2022355381A1/en active Pending
- 2022-09-28 US US18/696,559 patent/US20250042995A1/en active Pending
- 2022-09-28 WO PCT/CN2022/122185 patent/WO2023051621A1/zh not_active Ceased
- 2022-09-28 CA CA3233205A patent/CA3233205A1/en active Pending
- 2022-09-28 MX MX2024003936A patent/MX2024003936A/es unknown
- 2022-09-28 JP JP2024519329A patent/JP2024536881A/ja active Pending
- 2022-09-28 KR KR1020247012890A patent/KR20240083095A/ko active Pending
- 2022-09-28 CN CN202211192782.4A patent/CN115873116A/zh active Pending
- 2022-09-29 KR KR1020247014429A patent/KR20240083096A/ko active Pending
- 2022-09-29 CN CN202211199026.4A patent/CN115873123A/zh active Pending
- 2022-09-29 WO PCT/CN2022/122556 patent/WO2023051683A1/zh not_active Ceased
- 2022-09-29 EP EP22875065.9A patent/EP4410837A4/en active Pending
- 2022-09-29 CA CA3233192A patent/CA3233192A1/en active Pending
- 2022-09-29 IL IL311692A patent/IL311692A/en unknown
- 2022-09-29 AU AU2022355986A patent/AU2022355986A1/en active Pending
- 2022-09-29 US US18/696,546 patent/US20240392040A1/en active Pending
- 2022-09-29 JP JP2024520079A patent/JP2024538669A/ja active Pending
- 2022-09-29 MX MX2024003935A patent/MX2024003935A/es unknown
-
2024
- 2024-04-26 ZA ZA2024/03273A patent/ZA202403273B/en unknown
- 2024-04-26 ZA ZA2024/03275A patent/ZA202403275B/en unknown